Evaluation of neurotoxicity of TIQ and MPTP and of parkinsonism-preventing effect of 1-MeTIQ by in vivo measurement of pre-synaptic dopamine transporters and post-synaptic dopamine D2 receptors in the mouse striatum

Journal of Neurochemistry

Volumn 79, Issue 4, 2001, Pages 868-876

  Ishiwata, Kiichi ^a,b   Koyanagi, Yasuhiro ^a,b   Abe, Kenji ^a,b   Kawamura, Kazunori ^a,b   Taguchi, Kyoji ^a,b   Saitoh, Toshiaki ^a,b   Toda, Jun ^a,b   Senda, Michio ^a,b   Sano, Takehiro ^a,b  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

1,2,3,4 Tetrahydroisoquinoline; 1 Methyl 1,2,3,4 tetrahydroisoquinoline; Dopamine transporter; MPTP; Neuroprotection; Parkinsonism

Indexed keywords

1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; RADIOLIGAND; TETRAHYDROISOQUINOLINE; TETRAHYDROISOQUINOLINE DERIVATIVE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; BRADYKINESIA; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DRUG EFFECT; ENANTIOMER; IN VIVO STUDY; LIGAND BINDING; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BINDING, COMPETITIVE; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOKINESIA; ISOQUINOLINES; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED C57BL; NERVE TISSUE PROTEINS; PARKINSONIAN DISORDERS; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; STEREOISOMERISM; SUBSTANTIA NIGRA; SYNAPSES; TETRAHYDROISOQUINOLINES; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

ANIMALIA;

EID: 0035190389     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00619.x     Document Type: Article

References (46)

1. Biological and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse
2. Stereoselective effect of (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinolines on a mouse model of Parkinson's disease
3. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-Dopa treatment
4. 123I] FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys
5. +
6. Stereospecific prevention by 17β-estradiol of MPTP-induced dopamine depletion in mice
7. Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinsonis disease
8. β-carboline analogues N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP): Endogenous factors underlying idiopathic parkinsonism?
9. 11C-raclopride is altered by drugs that modify synaptic dopamine levels
10. The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on presynaptic dopamine uptake sites in the mouse striatum
11. Dopamine-derived alkaloids in alcoholism and in Parkinson's and Huntington's disease
12. 2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism
13. Dopamine transporter loss and clinical changes in MPTP-lesioned primates
14. Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice
15. Animal models of Parkinsonís disease: An empirical comparison with the phenomenology of the disease in man
16. Neurotensin receptors and dopamine transporters: Effects of MPTP lesioning and chronic dopaminergic treatments in monkeys
17. Amphetamine effects on dopamine release and synthesis rate studied in the rhesus monkey brain by positron emission tomography
18. 11C]raclopride binding in rat striatum, quantified using PET
19. Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density
20. 18F]GBR 13119 in MPTP-treated C57BL/6 mice
21. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice
22. Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present as novel endogenous amines in rat brain
23. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as parkinsonism-inducing agent: A novel endogenous amine in mouse brain and parkinsonian CSF
24. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate
25. Neurotoxins, parkinsonism and Parkinson's disease
26. Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats
27. 11 C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: Preparation, autoradiography, metabolite studies, and positron emission tomography examinations
28. Confirmation of the enantiomers of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization
29. Dopamine release within forebrain sites perfused with tetrahydroisoquinolines or tryptoline in the rat
30. Isoquinoline neurotoxins in the brain and Parkinson's disease
31. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions
32. 11C]β-CFT
33. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in parkinsonian and normal human brains
34. A simple quantitative bradykinesia test in MPTP-treated mice
35. The effect of 1,2,3,4-tetrahydroisoquinoline (TIQ) on mesencephalic dopaminergic neurons in C57BL/6J mice: Immunohistochemical studies-tyrosine hydroxylase
36. Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain: Relation to Parkinson's disease
37. GDNF protects against 6-OHDA nigrostriatal lesion: In vivo study with microdialysis and PET
38. MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans
39. Effects of GM1 ganglioside treatment on pre- and post-synaptic dopaminergic markers in the striatum of parkinsonian monkeys
40. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine
41. 3H raclopride: Implications for positron emission tomography of the human brain
42. A highly efficient synthesis of 1-methyl, 1-benzyl, and 1-phenyl-1,2,3,4-tetrahydroisoquinolines by modified Pummerer reaction
43. Determination of ring conformation in 1-benzyl-1,2,3,4-tetrahydroisoquinolines and a new synthesis of the chiral compounds
44. 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities
45. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds
46. 2 receptors in relation to expression of and recovery from experimental parkinsonism